Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$136.52

2.62 (1.96%)

, V

Visa

$108.42

1.11 (1.03%)

10:24
10/11/17
10/11
10:24
10/11/17
10:24

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying J&J's Pharma division is "under-modeled" by analysts and will drive above-consensus revenue and earnings growth. 2. Visa (V) and MasterCard (MA) were upgraded to Outperform from Market Perform at Wells Fargo. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. 4. AbbVie (ABBV) upgraded to Outperform from Market Perform at Cowen with analyst Steve Scala saying AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week. 5. PayPal (PYPL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

JNJ

Johnson & Johnson

$136.52

2.62 (1.96%)

V

Visa

$108.42

1.11 (1.03%)

MA

MasterCard

$146.42

0.77 (0.53%)

CL

Colgate-Palmolive

$74.68

1.78 (2.44%)

ABBV

AbbVie

$91.91

0.74 (0.81%)

PYPL

PayPal

$66.04

-0.19 (-0.29%)

  • 11

    Oct

  • 11

    Oct

  • 11

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 27

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 08

    Nov

  • 29

    Nov

JNJ Johnson & Johnson
$136.52

2.62 (1.96%)

10/11/17
JEFF
10/11/17
UPGRADE
Target $157
JEFF
Buy
Johnson & Johnson upgraded to Buy from Hold at Jefferies
Jefferies analyst Jeffrey Holford upgraded Johnson & Johnson to Buy while raising his price target for the shares to $157 from $145. The healthcare giant closed yesterday up 36c to $133.90. J&J's Pharma division is "under-modelled" by analysts and will drive above-consensus revenue and earnings growth, Holford tells investors in a research note. He sees the company's TIRADE pharma assets, or Tremfya, Imbruvica, rivaroxaban, Apalutamide, Darzalex, Esketamine and Stelara, as well as synergies from the Actelion acquisition, driving strong earnings momentum and better than expected dividends. Holford expects J&J shares to re-rate to a 10% market premium.
10/09/17
10/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Larry Biegelsen saying J&J is poised to reaccelerate its sales growth due to accretion from the Actelion acquisition, a "more measured" than expected impact from biosimilar competition, "solid performance" of key drugs and a pipeline that is "coming to fruition." 2. Morgan Stanley (MS) upgraded to Outperform from Neutral at Credit Suisse with analyst Susan Roth Katzke citing the over 10% total return potential in the shares. 3. Disney (DIS) upgraded to Top Pick from Outperform at RBC Capital with analyst Steven Cahall saying he thinks the company has reached a turning point with ESPN approaching less than 20% of earnings and "non-Media" Disney remaining a global leader in content that is executing well. 4. INC Research (INCR) upgraded to Buy from Hold at Jefferies analyst David Windley saying the recent share pullback provides a "compelling" entry point. 5. British American Tobacco (BTI) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/17
10/09/17
NO CHANGE

Valuations in Medical Technology look more attractive, says RBC Capital
RBC Capital analyst Glenn Novarro says the recent pullback in Medical Technology stocks since Q2 earnings has eliminated the valuation gap relative to other S&P Health Care subsectors. The analyst recommends a "Buy Now" for Johnson & Johnson (JNJ) and "Buy on Weakness" for Abbott Laboratories (ABT) among diversified MedTech names. In Cardiovascular, Novarro says "Buy Now" for Edwards Lifesciences (EW) and "Buy on Weakness" for Boston Scientific (BSX). For Nuvasive (NUVA) and Wright Medical (WMGI), the analyst says management will cut guidance because of hurricane related revenue shortfalls, but the selloff over the past several weeks is already discounting those expectations.
10/09/17
WELS
10/09/17
UPGRADE
Target $149
WELS
Outperform
Johnson & Johnson upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Larry Biegelsen upgraded Johnson & Johnson to Outperform and raised his price target for the shares to $149 from $140. The healthcare giant closed Friday up 1c to $133.22. J&J is poised to reaccelerate its sales growth due to accretion from the Actelion acquisition, a "more measured" than expected impact from biosimilar competition, "solid performance" of key drugs and a pipeline that is "coming to fruition," Biegelsen tells investors in a research note. Further, the analyst believes Johnson & Johnson could continue to deliver margin improvement and faster earnings growth.
V Visa
$108.42

1.11 (1.03%)

10/10/17
WELS
10/10/17
UPGRADE
Target $120
WELS
Outperform
Visa upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo transferred coverage of Visa to Donald Fandetti who upgraded the stock to Outperform form Market Perform with a $120 price target. Fandetti believes Visa's earnings model for the networks remains very much intact and are supported by pricing power and significant capital return. He expects positive earnings revisions in 2018 and for Visa Europe integration to ultimately drive expense synergies as processing systems are consolidated.
09/29/17
09/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Regeneron (REGN) assumed with an Overweight at Piper Jaffray. 2. MasterCard (MA) and Visa (V) were initiated with an Overweight at Cantor Fitzgerald. 3. Liberty Global (LBTYA, LBTYK) and Liberty Global LiLAC (LILA) were initiated with a Buy at Buckingham. 4. Corbus Pharmaceuticals (CRBP) coverage assumed with a Buy at Noble Financial. 5. Medpace (MEDP) initiated with a Market Perform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
BUCK
10/02/17
INITIATION
Target $129
BUCK
Buy
Visa initiated with a Buy at Buckingham
Buckingham analyst Chris Brendler started Visa with a Buy rating and $129 price target, saying he still views the payments networks as the stocks to own long-term in the increasingly attractive payments sector.
10/11/17
WELS
10/11/17
UPGRADE
Target $160
WELS
Outperform
MasterCard upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Donald Fandetti took over coverage of MasterCard (MA) with an Outperform rating and $160 price target, up from the firm's prior rating of Market Perform and $130 price target. Fandetti, who believes MasterCard is well positioned to deliver roughly 20% EPS growth, has a near-term preference for Visa (V), citing valuation and Visa Europe.
MA MasterCard
$146.42

0.77 (0.53%)

10/02/17
BUCK
10/02/17
INITIATION
Target $163
BUCK
Buy
MasterCard initiated with a Buy at Buckingham
Buckingham analyst Chris Brendler started MasterCard with a Buy rating and $163 price target, saying he still views the payments networks as the stocks to own long-term in the increasingly attractive payments sector.
09/28/17
CANT
09/28/17
INITIATION
Target $165
CANT
Overweight
MasterCard initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated MasterCard with an Overweight rating and $165 price target.
CL Colgate-Palmolive
$74.68

1.78 (2.44%)

10/11/17
RHCO
10/11/17
UPGRADE
Target $85
RHCO
Buy
Colgate-Palmolive upgraded to Buy at SunTrust
As previously noted, SunTrust analyst William Chappell upgraded Colgate-Palmolive to Buy from Hold and raised his price target on the stock to $85 from $65. Chappell says the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. The analyst also points to reacceleration in the emerging market middle class growth and favorable foreign exchange conditions for the first time in years.
10/11/17
RHCO
10/11/17
UPGRADE
RHCO
Buy
Colgate-Palmolive upgraded to Buy from Hold at SunTrust
09/25/17
MSCO
09/25/17
UPGRADE
MSCO
Overweight
Colgate-Palmolive upgraded to Overweight from Equal Weight at Morgan Stanley
09/25/17
09/25/17
UPGRADE
Target $84

Overweight
Colgate-Palmolive upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Dara Mohsenian upgraded Colgate-Palmolive to Overweight from Equal Weight and called the stock his top household products pick, saying he sees the company returning to above-peer growth beginning in Q4 and he thinks investors will soon "flock back" to emerging-market-centric names, like Colgate. The analyst, who thinks Colgate's valuation is attractive, also believes the company has multiple plausible strategic partners, unlike most peers. Mohsenian raised his price target on the stock to $84 from $75.
ABBV AbbVie
$91.91

0.74 (0.81%)

10/09/17
WBLR
10/09/17
NO CHANGE
Target $110
WBLR
Outperform
AbbVie fair value estimate raised to $110 from $76 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate for AbbVie to $110 to reflect progress with the pipeline and the recent Humira patent victory. The analyst now models Humira to maintain U.S. patent exclusivity through the end of 2022, extended from her previous estimate of 2020. Xu believes pivotal data readouts through year-end 2017 will continue to support the outperformance of AbbVie shares. She keeps an Outperform rating on the name.
10/02/17
10/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Akamai (AKAM) upgraded to Buy from Neutral at Guggenheim with analyst Robert Gutman citing valuation and raised its price target to $54 from $53. 2. Generac (GNRC) upgraded to Overweight from Sector Weight at KeyBanc with analyst Jeffrey Hammond saying the company is positioned to "meaningfully" re-accelerate growth and beat earnings expectations over the next 12-18 months. 3. Abercrombie & Fitch (ANF) upgraded to Hold from Sell at Argus with analysts John Eade and Annie Petrino saying new management is beginning to turn the operations around and shares have fallen to fallen for the past five years. 4. eGain (EGAN) upgraded to Buy from Hold at Craig-Hallum with analyst Jeff Van Rhee citing forward momentum building and compelling valuation. 5. AbbVie (ABBV) upgraded to Outperform from Market Perform at Leerink with analyst Geoffrey Porges saying he believes that there is still further upside as medium-and long-term estimates increase, and the company's multiple re-rates toward biopharmaceutical peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/17
COWN
10/11/17
UPGRADE
Target $105
COWN
Outperform
AbbVie upgraded to Outperform from Market Perform at Cowen
Cowen analyst Steve Scala upgraded AbbVie to Outperform and raised his price target for the shares to $105 from $95. AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week, Scala tells investors in a research note. He increased his out-year estimates for AbbVie after several of its drugs were highlighted during the conference. The stock is attractively valued versus the group overall, Scala argues.
10/09/17
LEER
10/09/17
NO CHANGE
LEER
Leerink not worried about JAK safety, AbbVie '494 profile so far 'ok'
Leerink analyst Geoffrey Porges notes that the delayed approval of Incyte (INCY)/Eli Lilly (LLY) baricitinib and the reported thromboembolic events in AbbVie's (ABBV) ABT494/upadacitinib trials have called into question the safety of oral Janus kinase, or JAK, inhibitors. The analyst says that his detailed review of the safety literature suggests that these medicines offer an acceptable risk/benefit profile for serious inflammatory diseases and do not confer a significant increase in cardiovascular risk or venous thromboembolic events. Further, Porges continues to believe AbbVie's upadacitinib and Gilead's (GILD) filgotinib will be approved for serious inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, and will capture the majority share of his peak risk-adjusted $12B estimated JAK market.
PYPL PayPal
$66.04

-0.19 (-0.29%)

10/06/17
BOFA
10/06/17
NO CHANGE
Target $78
BOFA
Buy
PayPal price target raised to $78 from $71 at BofA/Merrill
BofA/Merrill analyst Jason Kupferberg raised PayPal's Q3 revenue estimate to $3.203B from $3.181B, above the top end of guidance. His Q3 non-GAAP estimate is 44c, in line with consensus and the high end of guidance. Kupferberg continues to believe PayPal is the best positioned company under coverage to capitalize on the global mix shift of payments from offline to online/digital channels. The analyst reiterated his Buy rating ahead of the Q3 report on October 19 and increased his price target to $78 from $71 to reflect a modest increase in 2019 estimates.
10/11/17
10/11/17
UPGRADE
Target $76

Overweight
PayPal upgraded to Overweight on revised view of eBay risk at Morgan Stanley
As previously reported, Morgan Stanley analyst James Faucette upgraded PayPal (PYPL) to Overweight from Equal Weight, calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. While he previously was on the sidelines due to risk from its contract renegotiation with eBay (EBAY), he now believes the market may be overly concerned with it as he thinks the most likely renewal structure will feature rebates from PayPal to eBay, he tells investors. Faucette raised his price target on PayPal shares to $76 from $62. He also raised his price target on eBay to $33 from $29, though he keeps an Underweight rating on its shares.
10/11/17
MSCO
10/11/17
UPGRADE
MSCO
Overweight
PayPal upgraded to Overweight from Equal Weight at Morgan Stanley
10/10/17
FBCO
10/10/17
NO CHANGE
Target $70
FBCO
Outperform
PayPal price target raised to $70 from $63 at Credit Suisse
Credit Suisse analyst Paul Condra raised his price target for PayPal to $70 from $63 as he continues to like the stock primarily for its pure-play exposure to online/mobile commerce and the potential growth opportunities inherent to this industry. The analyst believes the market underestimates the stickiness of the PayPal platform and expects the brand could gain strength globally as its newly established tech/finance relationships deepen and evolve. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

00:00
02/22/18
02/22
00:00
02/22/18
00:00
General news
Breaking General news story  »

Federal Reserve Vice…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

, HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

20:25
02/21/18
02/21
20:25
02/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

APA

Apache

$37.20

-1.1 (-2.87%)

LDOS

Leidos

$65.21

-1.02 (-1.54%)

W

Wayfair

$95.69

-0.61 (-0.63%)

OA

Orbital ATK

$131.80

-0.02 (-0.02%)

TREE

LendingTree

$371.25

-7.8 (-2.06%)

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

TPX

Tempur Sealy

$54.97

1.17 (2.17%)

SAFM

Sanderson Farms

$128.00

-3.44 (-2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

20:04
02/21/18
02/21
20:04
02/21/18
20:04
Syndicate
Aimmune 5.5M share Secondary priced at $32.00 »

BofA/Merrill, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 11

    Mar

  • 22

    Feb

20:00
02/21/18
02/21
20:00
02/21/18
20:00
General news
Breaking General news story  »

Minneapolis Federal…

NUAN

Nuance

$16.28

-0.28 (-1.69%)

19:10
02/21/18
02/21
19:10
02/21/18
19:10
Periodicals
Nuance discontinues Swype feature development, Verge reports »

Nuance has ceased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SSNLF

Samsung

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

19:04
02/21/18
02/21
19:04
02/21/18
19:04
Hot Stocks
Samsung, Qualcomm expand foundry cooperation on EUV process technology »

Samsung Electronics…

SSNLF

Samsung

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

CATY

Cathay General

$42.84

0.43 (1.01%)

18:59
02/21/18
02/21
18:59
02/21/18
18:59
Hot Stocks
Cathay General executive chairman Cheng sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$30.00

-0.08 (-0.27%)

18:42
02/21/18
02/21
18:42
02/21/18
18:42
Earnings
Sunoco reports Q4 EPS $2.01, may not compare to consensus 35c »

Reports Q4 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

USFD

US Foods

$32.29

0.33 (1.03%)

18:39
02/21/18
02/21
18:39
02/21/18
18:39
Hot Stocks
US Foods director Lederer sells 98,702 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:38
02/21/18
02/21
18:38
02/21/18
18:38
Earnings
Volaris reports Q4 28c, consensus 20c »

Reports Q4 revenue $336M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:34
02/21/18
02/21
18:34
02/21/18
18:34
Earnings
Breaking Earnings news story on Volaris »

Volaris reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:29
02/21/18
02/21
18:29
02/21/18
18:29
Earnings
Valmont sees 2018 adjusted $8.00, consensus $8.15 »

Sees 2018 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:27
02/21/18
02/21
18:27
02/21/18
18:27
Earnings
Valmont reports Q4 adjusted EPS $1.67, consensus $1.69 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

CTRV

ContraVir Pharmaceuticals

$0.25

-0.013 (-5.00%)

18:11
02/21/18
02/21
18:11
02/21/18
18:11
Hot Stocks
ContraVir Pharmaceuticals' hepatitis B treatment receives FDA Orphan designation »

ContraVir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:06
02/21/18
02/21
18:06
02/21/18
18:06
Earnings
AAC Holdings sees FY18 adjusted EPS 70c-75c, consensus 53c »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:05
02/21/18
02/21
18:05
02/21/18
18:05
Earnings
AAC Holdings reports Q4 adjusted EPS 10c, consensus 4c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DNKN

Dunkin' Brands

$60.70

-1.45 (-2.33%)

18:04
02/21/18
02/21
18:04
02/21/18
18:04
Hot Stocks
Baskin-Robbins expands in Toronto with plans for four new locations »

Baskin-Robbins, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$102.43

0.05 (0.05%)

18:01
02/21/18
02/21
18:01
02/21/18
18:01
Hot Stocks
Celanese to increase price of acetyl intermediate products »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 30

    May

TUSK

Mammoth Energy

$20.04

-0.11 (-0.55%)

17:56
02/21/18
02/21
17:56
02/21/18
17:56
Earnings
Mammoth Energy reports Q4 EPS $1.48, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

NSPR

InspireMD

$4.20

-0.26 (-5.83%)

17:53
02/21/18
02/21
17:53
02/21/18
17:53
Syndicate
Breaking Syndicate news story on InspireMD »

InspireMD files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETFC

E-Trade

$51.76

-0.25 (-0.48%)

17:52
02/21/18
02/21
17:52
02/21/18
17:52
Syndicate
Breaking Syndicate news story on E-Trade »

E-Trade files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$39.91

1.01 (2.60%)

17:47
02/21/18
02/21
17:47
02/21/18
17:47
Syndicate
Breaking Syndicate news story on Spirit Airlines »

Spirit Airlines files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAND

Bandwidth

$24.09

0.18 (0.75%)

, CAR

Avis Budget

$38.96

-0.98 (-2.45%)

17:42
02/21/18
02/21
17:42
02/21/18
17:42
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

BAND

Bandwidth

$24.09

0.18 (0.75%)

CAR

Avis Budget

$38.96

-0.98 (-2.45%)

MB

Mindbody

$33.35

-0.1 (-0.30%)

SAIL

SailPoint Technologies

$17.92

0.47 (2.69%)

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

GPOR

Gulfport Energy

$8.41

-0.32 (-3.67%)

SNPS

Synopsys

$88.46

-1.3 (-1.45%)

PE

Parsley Energy

$23.10

-0.19 (-0.82%)

P

Pandora

$4.87

-0.46 (-8.63%)

MLNX

Mellanox

ROKU

Roku

$51.10

-0.08 (-0.16%)

AAOI

Applied Optoelectronics

$34.55

1.22 (3.66%)

SRCL

Stericycle

$74.91

-0.31 (-0.41%)

CSLT

Castlight Health

$3.85

0.3 (8.45%)

UCTT

Ultra Clean

$19.96

-0.4 (-1.96%)

TRN

Trinity Industries

$35.23

0.47 (1.35%)

RGR

Sturm, Ruger

$47.30

-1.05 (-2.17%)

CONE

CyrusOne

$48.81

-1.56 (-3.10%)

ADXS

Advaxis

$2.51

-0.08 (-3.09%)

GWPH

GW Pharmaceuticals

$132.33

1.5 (1.15%)

OMF

OneMain Holdings

$31.67

-0.22 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 11

    Mar

  • 13

    Mar

  • 14

    Mar

  • 21

    Mar

  • 26

    Mar

  • 28

    Mar

  • 29

    Mar

  • 03

    Apr

  • 15

    May

  • 23

    May

  • 27

    Jun

  • 22

    Feb

CLI

Mack-Cali Realty

$18.33

-0.25 (-1.35%)

17:40
02/21/18
02/21
17:40
02/21/18
17:40
Earnings
Breaking Earnings news story on Mack-Cali Realty »

Mack-Cali Realty sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLI

Mack-Cali Realty

$18.33

-0.25 (-1.35%)

17:39
02/21/18
02/21
17:39
02/21/18
17:39
Earnings
Breaking Earnings news story on Mack-Cali Realty »

Mack-Cali Realty reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.